All In Biotech

Drug Trial Radar · NCT07681089

A Phase 2 Study of Foscenvivint in Liver Cirrhosis Patients Caused by HIV/HCV Co-infection With Hemophilia

A Multicenter, Single-Arm, Open-Label Phase 2 Study of Once-Weekly Foscenvivint in Patients With Liver Cirrhosis Due to HIV/HCV Co-infection in the Setting of Hemophilia

Last checked: Nov 20, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

7

Planned (sponsor's estimate)

Start

Oct 1, 2026

Primary completion

Nov 30, 2027

Study completion Mar 31, 2028

Sponsor

Lead sponsor
Kiminori Kimura, MDAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Japan Agency for Medical Research and Development; Ohara Pharmaceutical Co., Ltd.
First posted
Jul 2, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 79 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 2 study to evaluate the efficacy and safety of foscenvivint in patients with liver cirrhosis resulting from HIV/HCV co-infection in the setting of hemophilia.

Conditions

  • Liver Cirrhosis

Interventions

  • FoscenvivintDrug

    Experimental:Foscenvivint Administered by intravenous (IV) infusion over 3-4 hours Arm Description:Foscenvivint 280 mg/m2, once a week for 24 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. ALBI scoreTime frame: Baseline to 24 weeks after administration

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Hokkaido University Hospital

    Sapporo, Hokkaido, Japan · Recruiting

  • National Hospital Organization Sendai Medical Center

    Sendai, Miyagi, Japan · Recruiting

  • National Hospital Organization Osaka National Hospital

    Osaka, Osaka, Japan · Recruiting

  • Tokyo Metropolitan Komagome Hospital

    Bunkyo-Ku, Tokyo, Japan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.